Cambridge Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Cambridge Trust’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$9.63K	Sell	10 -147	-94%	-$140K	﹤0.01%	579
2023 Q4	$138K	Sell	157 -11	-7%	-$9.06K	0.01%	309
2023 Q3	$138K	Buy	168 +11	+7%	+$8.64K	0.01%	308
2023 Q2	$113K	Hold	157	–	–	0.01%	342
2023 Q1	$129K	Hold	157	–	–	0.01%	326
2022 Q4	$113K	Buy	157 +4	+3%	+$2.95K	0.01%	346
2022 Q3	$105K	Hold	153	–	–	0.01%	355
2022 Q2	$91K	Hold	153	–	–	﹤0.01%	408
2022 Q1	$107K	Sell	153 -14	-8%	-$8.86K	﹤0.01%	417
2021 Q4	$106K	Buy	+167	New	+$103K	﹤0.01%	414

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Cambridge Trust's REGN Position: Q1 2024 in Review

Cambridge Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 94% in Q1 2024, selling an estimated $140K and leaving 10 shares worth $9.63K. The position accounts for ﹤0.01% of the portfolio, ranked #579.

Cambridge Trust first reported a position in REGN in Q4 2021 and has held it in 10 quarters since. The position peaked at $138K in Q3 2023. 1,312 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

Cambridge Trust held 10 shares of Regeneron Pharmaceuticals worth $9.63K as of Q1 2024.
Cambridge Trust sold 147 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $140K.
Regeneron Pharmaceuticals made up ﹤0.01% of Cambridge Trust's portfolio in Q1 2024, its #579 holding.
Cambridge Trust first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Cambridge Trust's Regeneron Pharmaceuticals position peaked at $138K in Q3 2023.
1,312 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.